<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051532</url>
  </required_header>
  <id_info>
    <org_study_id>EBC 9801 INT</org_study_id>
    <secondary_id>EBC 9801 INT</secondary_id>
    <nct_id>NCT00051532</nct_id>
  </id_info>
  <brief_title>Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5ug) or Placebo in the Treatment of Patients With Hepatocellular Carcinoma Not Amenable to Curative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether seocalcitol is effective in the treatment of
      advanced primary liver cancer (hepatocellular carcinoma [HCC]).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 1999</start_date>
  <completion_date>May 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Educational/Counseling/Training</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival, defined as the time from start of treatment to death</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCC-specific survival from start of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response from start of treatment (complete or partial response)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve partial/complete response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression measured from start of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response in patients showing a complete response, measured from the first date when absence of disease was recorded until the first date of disease progression was recorded</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of partial response in patients showing partial response, measured from first date when partial response was recorded until the first date at which disease progression was observed</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease measured from start of treatment until the first date where either progression or partial/complete response was observed</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change(s) in tumour size</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumour marker</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalisation (in-patient care)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory values</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of seocalcitol (seocalcitol treated patients)</measure>
  </secondary_outcome>
  <enrollment>700</enrollment>
  <condition>Liver Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seocalcitol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospital in- or out-patients

          -  Either sex

          -  Aged 18-75 years

          -  With hepatocellular carcinoma, verified by histology/cytology, which is not amenable
             to curative treatment or transplantation.

          -  Patients must have measurable disease, and be classifiable as to Barcelona Clinic
             Liver Cancer (BCLC) stage 0, as described in Llovet JM et al. Hepatology
             1999;29:62-67.

        Exclusion Criteria:

          -  Patients treated with chemotherapy or other anti-cancer therapy within 4 weeks before
             visit 1

          -  Patients with another primary tumor, except for basocellular carcinoma of the skin or
             in situ carcinoma of the cervix, within the last 2 years

          -  A history of renal stone(s)

          -  A life expectancy of &lt; 3 months

          -  World Health Organization (WHO) performance status 3 or 4

          -  Okuda stage III.

          -  Patients with hypercalcemia, or other clinically important laboratory abnormalities

          -  Patients with previous/current calcium metabolic disease, taking calcium-lowering
             therapy, or medication known to affect systemic calcium metabolism are also excluded.

          -  All patients must give their signed informed consent to join the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanne Hvidberg, MSc Pharm, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>E.g. University Health Network Toronto General Hospital (numerous facilities are recruiting in Canada)</name>
      <address>
        <city>Toronto</city>
        <state>Alberta</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.g. Notre-Dame de Bon Secours, Service dÂ´Hepato-Gastro-Enterologie (numerous facilities are recruiting in France)</name>
      <address>
        <city>Metz</city>
        <zip>F-57038 Metz Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.g. Osp. Maggiore, Policlinico di Milano (numerous facilities are recruiting in Italy)</name>
      <address>
        <city>Milano</city>
        <zip>I-20 122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.g. Hospital Clinic Provincial de Barcelona (numerous facilities are recruiting in Spain)</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.g. The University of Edinburgh Royal Infirmary (numerous facilities are recruiting in UK)</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH39YW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com</url>
    <description>Click here for more information about this study: Drug Development, Pipeline, Seocalcitol</description>
  </link>
  <verification_date>April 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2003</study_first_submitted>
  <study_first_submitted_qc>January 13, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2003</study_first_posted>
  <last_update_submitted>March 5, 2007</last_update_submitted>
  <last_update_submitted_qc>March 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2007</last_update_posted>
  <keyword>hepatocellular</keyword>
  <keyword>carcinoma</keyword>
  <keyword>liver</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seocalcitol</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

